Vagus Nerve Stimulation Associated with Fewer Deaths in Hospitalized COVID-19 PatientsPosted by On

Vitality Smartcable Showing connector, circuit module and ear clip with electrodes.

Nemechek Technologies Vitality Smartcable Transcutaneous Vagus Nerve Stimulator is the first neuromodulator to run on your smartphone.

Dr. Patrick Nemechek reports on a promising clinical trial in the Journal of Clinical and Experimental Immunology

OVERLAND PARK, KANSAS, UNITED STATES, December 2, 2020 / — Nemechek Technologies is proud to announce publication of a peer-reviewed research article by its CEO, Patrick Nemechek D.O. Entitled, ‘Transcutaneous Vagus Nerve Stimulation is Associated with Lower Mechanical Ventilation and Mortality in COVID-19 Patients: An interim Safety Analysis’, the study reveals that transcutaneous vagus nerve stimulation (tVNS) is safe and potentially beneficial for hospitalized patients with COVID-19 pneumonia. Patients meeting clinical criteria received tVNS therapy for 5 minutes 2-4 times per day with the Nemechek Technologies Vitality Smartcable® neuromodulator.

Patient outcomes included infrequent use of mechanical ventilation, and a high rate of survival. Interim analysis found the mortality rate and the frequency of mechanical ventilation to be less than almost all other large COVID-19 cohorts. The study, an ongoing single-arm, uncontrolled open-label, observational trial to assess (tVNS) in hospitalized SARS-CoV-2 infected subjects, is being conducted at…

Original Author Link click here to read complete story..



Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.